Web of Science: 102 cites, Scopus: 116 cites, Google Scholar: cites,
Advances in Parkinson's Disease : 200 Years Later
Del Rey, Natalia López-González (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Quiroga-Varela, Ana (Department of Neuroscience, Centro de Investigación Médica Aplicada (CIMA), University of Navarra)
Garbayo, Elisa (Instituto de Investigación Sanitaria de Navarra)
Carballo-Carbajal, Iria (Hospital Universitari Vall d'Hebron)
Fernández-Santiago, Rubén (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Monje, Mariana H. G. (Universidad Autónoma de Madrid. Departamento de Anatomía, Histología y Neurociencia)
Trigo-Damas, Inés (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Blanco-Prieto, María J. (Instituto de Investigación Sanitaria de Navarra)
Blesa, Javier (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas)
Universitat Autònoma de Barcelona

Data: 2018
Resum: When James Parkinson described the classical symptoms of the disease he could hardly foresee the evolution of our understanding over the next two hundred years. Nowadays, Parkinson's disease is considered a complex multifactorial disease in which genetic factors, either causative or susceptibility variants, unknown environmental cues, and the potential interaction of both could ultimately trigger the pathology. Noteworthy advances have been made in different fields from the clinical phenotype to the decoding of some potential neuropathological features, among which are the fields of genetics, drug discovery or biomaterials for drug delivery, which, though recent in origin, have evolved swiftly to become the basis of research into the disease today. In this review, we highlight some of the key advances in the field over the past two centuries and discuss the current challenges focusing on exciting new research developments likely to come in the next few years. Also, the importance of pre-motor symptoms and early diagnosis in the search for more effective therapeutic options is discussed.
Ajuts: Ministerio de Economía y Competitividad SAF2015-73508-JIN
Nota: Altres ajuts: The authors NDR, IT-D, and JB are currently funded by grant S2017/BMD-3700 (NEUROMETAB-CM) from Comunidad de Madrid co-financed with the Structural Funds of the European Union, Fundación BBVA and Fundación Tatiana Pérez de Guzmán el Bueno.
Drets: Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. Creative Commons
Llengua: Anglès
Document: Article de revisió ; Article ; Versió publicada
Matèria: Parkinson's disease ; Genetics ; Drug delivery systems ; Non-motor symptoms ; Focused ultrasound
Publicat a: Frontiers in Neuroanatomy, Vol. 12 (december 2018) , ISSN 1662-5129

DOI: 10.3389/fnana.2018.00113
PMID: 30618654


14 p, 1.2 MB

El registre apareix a les col·leccions:
Articles > Articles publicats

 Registre creat el 2020-07-06, darrera modificació el 2024-11-18



   Favorit i Compartir